CA-AVIATRIX
9.3.2021 15:02:11 CET | Business Wire | Press release
Aviatrix , the cloud network platform, today announced the availability of the 2021 Forrester's Total Economic Impact™ (TEI) Study commissioned by Aviatrix, conducted independently by Forrester Consulting in January 2021. The TEI Study is based on Forrester's in-depth interviews with Aviatrix customers and provides a quantitative, business value justification designed to help IT leaders. It demonstrates a composite cost-savings and business benefits analysis interviewed customers realized by leveraging the Aviatrix cloud network platform and provides a model for determining economic value in any organization.
The complete results of the TEI Study of Aviatrix can be found and downloaded here , where readers will learn how Aviatrix customers leverage more advanced cloud networking, security, and operational visibility for their cloud and multi-cloud network environments, helping them generate new revenue and ensure operational efficiency at significantly lower costs.
Key highlights of the TEI Study on Aviatrix cloud network platform Include:
- Aviatrix pays for itself more than 2x in the span of three years (222% ROI)
- Over $3 million in revenue and margin gains from new and existing customers attributed to multi-cloud readiness and faster time-to-market
- Over $1 million in cost savings from operational efficiency and resource re-allocation
- Over $4 million in business benefits and cost savings over three years
Cloud infrastructure is becoming the norm for many organizations. Decision makers may plan to focus on a single cloud platform, but they often need to support many due to acquisitions, client requirements, or app developer preferences. Each cloud service provider comes with its own processes, native constructs and tools that can slow cloud network operations. The Aviatrix cloud network platform helps organizations automate and control cloud network infrastructure, maintain security compliance, and respond to clients much faster.
Aviatrix customers saw significant benefits after deploying the company’s cloud network platform:
- “Without Aviatrix, it would have taken an extra year and twice the staff” — Sr. Infrastructure Architect, insurance company.
- “We have been able to open new lines of business and keep up with increased demand” — Assistant Director of Cloud Architecture and Engineering, manufacturer.
- “We can shine a light in the dark corners of public cloud [with Aviatrix]” — Senior Cloud Architect, business software and services provider.
- “With Aviatrix, we are saving millions” — Assistant Director of Cloud Architecture and Engineering, manufacturer.
“We’re very pleased with the overall results of the Forrester TEI Study,” said Rod Stuhlmuller, Vice President of Product Marketing at Aviatrix. “The quantifiable data truly highlights the benefits our customers receive using the Aviatrix cloud network platform. Furthermore, our customers achieve these benefits in both single and multi-cloud environments. As more enterprises adopt a multi-cloud strategy, Aviatrix’s market leading solutions will be the foundation for demonstratable economic gains.”
Executive Summary Video of the TEI Study on Aviatrix: (5 mins)
Watch guest speaker Sean Owens, Forrester’s Principal Consultant, and leader of the TEI of Aviatrix cloud network platform study, provide an executive summary of the study’s methodology, key findings, and quantified results. View video here.
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom